HAE
Haemonetics CorporationHealthcare · $4.7B market cap
Verdict
Share price
$104.68
close of Oct 3, 2026
Fair value
$86.59
Sticker Price
Payback Price
$34.64
buy price
HAE is Overpriced: at $104.68 it trades 21% above its fair value of $86.59. Its buy price (Payback Price) is $34.64, 67% below today's price. Business quality is limited: none of the 5 key numbers clears the 10% bar.
How we valued it
Owner Earnings. Earnings grow slowly (under 7% a year), but cash flow is steady, so we value it on its cash flow instead of its earnings.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow HAE
Get notified when it reaches its buy price of $34.64. Free.
Create a free accountSuperinvestors
2 of the investors we track hold HAE. In Q2 2026, 1 opened a position and 1 added. Who we track
Insider activity
Since Jul 24, 2026: no open-market purchases and 8 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Haemonetics Corporation
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated…
Medical - Devices
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works